Brief: Oramed Pharmaceuticals Has Screened First Patient In Its Ora-D-013-2 Study
23/03/2021 11:42
March 23 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED PHARMACEUTICALS - ON MARCH 23 ANNOUNCED THAT IT HAS
SCREENED FIRST PATIENT IN ITS ORA-D-013-2 STUDY
Source text for Eikon: ID:
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results